REGENXBIO Inc — Quarterly Financial Statistics (NASDAQ:RGNX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 40.55 M31.62 M33.63 M-17.92 M55.96 M 103.3 M Cash from investing activities 50.26 M40.27 M44.74 M50.95 M-42.29 M 93.68 M Cash from financing activities -10.86 M-7.74 M5.79 M127.64 M-7.08 M 118.61 M Free cash flow 40.22 M30.55 M32.6 M-18.31 M55.47 M 100.31 M

Haberler

FDA yorumları sonrası Stifel’den uniQure değerlendirmesi

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com

REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX)

Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection

Intel, Wells Fargo among market cap stock movers on Tuesday

Netflix and Oracle among market cap stock movers on Tuesday

Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback

REGENXBIO hisseleri FDA’nın Hunter sendromu için gen tedavisini reddetmesinin ardından düştü

After-hours movers: ON Semiconductor, Credo, Upwork, Regenxbio, and more